Skip to main navigation Skip to search Skip to main content

A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer (ABC)

  • MONTEMURRO F.
  • , CHOA G.
  • , FAGGIUOLO R.
  • , DONADIO M.
  • , MINISCHETTI M.
  • , DURANDO A.
  • , CAPALDI A.
  • , VIETTI RAMUS G.
  • , ALABISO Oscar
  • , AGLIETTA M.

Research output: Contribution to conferencePaper

Original languageEnglish
Pages48
Number of pages48
Publication statusPublished - 1 Jan 2003
Externally publishedYes
EventProc Am Soc Clin Oncol -
Duration: 1 Jan 2003 → …

Conference

ConferenceProc Am Soc Clin Oncol
Period1/01/03 → …

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this